178 related articles for article (PubMed ID: 35597872)
1. Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase.
Min HY; Lee HJ; Suh YA; Pei H; Kwon H; Jang HJ; Yun HJ; Moon HG; Lee HY
Br J Cancer; 2022 Sep; 127(4):661-674. PubMed ID: 35597872
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Calpain-2 Enhances Non-Small Cell Lung Cancer Progression and Chemoresistance to Paclitaxel via EGFR-pAKT Pathway.
Xu F; Gu J; Lu C; Mao W; Wang L; Zhu Q; Liu Z; Chu Y; Liu R; Ge D
Int J Biol Sci; 2019; 15(1):127-137. PubMed ID: 30662353
[TBL] [Abstract][Full Text] [Related]
4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
5. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
6. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
7. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
[TBL] [Abstract][Full Text] [Related]
11. Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras-Driven Tumor Growth or Metastasis.
Ghergurovich JM; Esposito M; Chen Z; Wang JZ; Bhatt V; Lan T; White E; Kang Y; Guo JY; Rabinowitz JD
Cancer Res; 2020 Sep; 80(18):3820-3829. PubMed ID: 32661137
[TBL] [Abstract][Full Text] [Related]
12. Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.
Zang F; Rao Y; Zhu X; Wu Z; Jiang H
Mol Med; 2020 Apr; 26(1):28. PubMed ID: 32268876
[TBL] [Abstract][Full Text] [Related]
13. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
[TBL] [Abstract][Full Text] [Related]
14. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
15. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
16. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
17. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
18. High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells.
Wang TH; Chen CC; Huang KY; Shih YM; Chen CY
Phytomedicine; 2019 Nov; 64():152926. PubMed ID: 31454652
[TBL] [Abstract][Full Text] [Related]
19. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
20. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
